Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMRX
stocks logo

AMRX

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
753.34M
+7.35%
0.170
+6.18%
777.45M
+10.67%
0.177
+10.81%
786.22M
+7.62%
0.151
+26.12%
Estimates Revision
The market is revising Downward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 11.78%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.81%
In Past 3 Month
Stock Price
Go Up
up Image
+11.78%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is 9.31 USD with a low forecast of 7.62 USD and a high forecast of 11.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 7.970
sliders
Low
7.62
Averages
9.31
High
11.00
up Image0
Current: 7.970
sliders
Low
7.62
Averages
9.31
High
11.00
Goldman Sachs
Matt Dellatorre
Buy
initiated
$12
2025-06-06
Reason
Goldman Sachs
Matt Dellatorre
Price Target
$12
2025-06-06
initiated
Buy
Reason
Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals with a Buy rating and $12 price target. The firm expects continued momentum across the portfolio and sees upside to consensus estimates. Goldman sees Amneal's generics segment remaining the key component and driver of EBITDA growth, driven by the company's strong product pipeline, including biosimilar and sterile injectable launches.
Barclays
Balaji Prasad
Buy
Maintains
$10 → $11
2025-03-03
Reason
Barclays
Balaji Prasad
Price Target
$10 → $11
2025-03-03
Maintains
Buy
Reason
JP Morgan
Chris Schott
Hold
to
Buy
Upgrades
$9 → $12
2025-02-24
Reason
JP Morgan
Chris Schott
Price Target
$9 → $12
2025-02-24
Upgrades
Hold
to
Buy
Reason
Piper Sandler
David Amsellem
Buy
Maintains
$9 → $11
2024-11-11
Reason
Piper Sandler
David Amsellem
Price Target
$9 → $11
2024-11-11
Maintains
Buy
Reason
Piper Sandler raised the firm's price target on Amneal Pharmaceuticals to $11 from $9 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 16c on revenue of $702M, compared to Street estimates of 13c and $694M, respectively. The company reiterated 2024 total revenue and adjusted EBITDA guidance ranges of $2.7B-$2.8B and $610M-$630M, respectively.
Truist Securities
Les Sulewski
Strong Buy
Maintains
$10 → $12
2024-10-02
Reason
Truist Securities
Les Sulewski
Price Target
$10 → $12
2024-10-02
Maintains
Strong Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Amneal Pharmaceuticals to $12 from $10 and keeps a Buy rating on the shares. The firm has followed up with the company's management post Metsera collaboration news to gain insight into the agreement and entrance into the GLP1 space as a supplier for U.S./E.U. markets and commercial leadership ex-U.S., the analyst tells investors in a research note. Despite Metsera's early stage foray into next-gen GLP1s, the partnership solidifies Amneal as a commercial partner with scale, opening the door for additional GLP1 manufacturing contracts, the firm states, adding that its $200M investment in a new India facility will leverage Amneal's complex manufacturing knowhow and boost its peptide footprint to drive additional partnerships.
JP Morgan
Chris Schott
Sell
to
Hold
Upgrades
$9
2024-09-06
Reason
JP Morgan
Chris Schott
Price Target
$9
2024-09-06
Upgrades
Sell
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX.N) is 12.33, compared to its 5-year average forward P/E of 7.43. For a more detailed relative valuation and DCF analysis to assess Amneal Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
7.43
Current PE
12.33
Overvalued PE
10.50
Undervalued PE
4.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average EV/EBITDA
6.73
Current EV/EBITDA
7.79
Overvalued EV/EBITDA
7.69
Undervalued EV/EBITDA
5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
0.44
Current PS
0.84
Overvalued PS
0.71
Undervalued PS
0.17

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

AMRX News & Events

Events Timeline

(ET)
2025-07-18
07:03:49
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
select
2025-06-25 (ET)
2025-06-25
08:07:09
Amneal Pharmaceuticals announces results from trial evaluating ADL-018
select
2025-06-12 (ET)
2025-06-12
08:03:01
Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
07-18Newsfilter
PinnedKnight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

  • New Drug Submission Accepted: Knight Therapeutics Inc. announced that Health Canada has accepted its New Drug Submission for CREXONT®, a novel oral formulation of carbidopa/levodopa for treating Parkinson's disease, which aims to address significant unmet medical needs in this area.

  • Clinical Study Success: The RISE-PD clinical study demonstrated that CREXONT® significantly improves "Good On" time with fewer doses compared to traditional treatments, indicating its potential as a valuable therapeutic option for patients with Parkinson's disease.

Preview
2.0
07-01NASDAQ.COM
Indivior (INDV) Moves 5.7% Higher: Will This Strength Last?

  • Stock Performance: Indivior PLC (INDV) shares rose 5.7% to $14.74, driven by positive investor sentiment regarding its addiction treatments, despite a projected decline in quarterly earnings and revenues.

  • Earnings Outlook: The consensus EPS estimate for Indivior remains unchanged at $0.25, indicating potential stability; meanwhile, Amneal Pharmaceuticals (AMRX) also shows steady performance with an unchanged EPS estimate of $0.17 and a Zacks Rank of #2 (Buy).

Preview
9.0
06-25Newsfilter
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

  • Amneal's Biosimilar Development: Amneal Pharmaceuticals has announced positive results from a clinical trial for ADL-018, a proposed biosimilar to XOLAIR (omalizumab), which is expected to be submitted for FDA approval in Q4 2025. The study demonstrated efficacy and safety comparable to the reference product.

  • Market Potential: With U.S. annual sales of XOLAIR reaching approximately $3.9 billion, Amneal aims to leverage its exclusive commercialization rights for ADL-018 as part of its strategy to expand its biosimilars portfolio by 2027.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) stock price today?

The current price of AMRX is 7.97 USD — it has decreased -3.28 % in the last trading day.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s business?

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

arrow icon

What is the price predicton of AMRX Stock?

Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is 9.31 USD with a low forecast of 7.62 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s revenue for the last quarter?

Amneal Pharmaceuticals Inc revenue for the last quarter amounts to 695.42M USD, increased 5.50 % YoY.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s earnings per share (EPS) for the last quarter?

Amneal Pharmaceuticals Inc. EPS for the last quarter amounts to 0.04 USD, decreased -113.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amneal Pharmaceuticals Inc (AMRX)'s fundamentals?

The market is revising Downward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 11.78%.
arrow icon

How many employees does Amneal Pharmaceuticals Inc (AMRX). have?

Amneal Pharmaceuticals Inc (AMRX) has 8100 emplpoyees as of July 19 2025.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) market cap?

Today AMRX has the market capitalization of 2.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free